{
  "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
  "docSlug": "97e34d6c4db7d9454440fee3efd43545",
  "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
  "authorId": "axcella-health",
  "authorName": "Axcella Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 11,
  "pageCount": 62,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a standard clinical trial flow diagram to illustrate study arms and assessment points.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/11",
  "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
  "deckJsonHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61.json",
  "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Clinical trial flow diagram showing screening, randomization, treatment arms, and follow-up.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66e8ec98-0613-4808-8181-df91db0ffe7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "ALT=alanine aminotransferase; BID=twice a day; D=day; IA=interim analysis; MRI-PDFF=magnetic resonance imaging of the hepatis proton density fat fraction; N=number of subjects; NAS=NAFLD Activity Score.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4338fdc7-7717-4e26-be7c-3dfdd4e538d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.63
      },
      "kind": "table",
      "text": "Core elements and descriptions of the study design.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56a252e4-9b99-4dea-b7e0-6353b1665344",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.26,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 2b Clinical Trial Underway",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd842eca-3f9f-4bfc-9bb0-e918a5e452ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.26,
        "y": 0.1
      },
      "kind": "title",
      "text": "Preplanned interim analysis when 30 subjects/arm reached week 12",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9af69add-a058-445f-9a7a-81a5f3733a0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "be199bb2-c88d-4fec-bad2-8b54c9d3e3f6",
      "evidence": "Standardized representation of patient flow and study arms in clinical research.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 36,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "de6af44a-f17d-4c55-adca-ab6e25c41e5d",
      "evidence": "The presentation highlights the need for effective treatment options and the risks associated with disease progression",
      "position": 0,
      "objective": "What is the risk of not treating NASH effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}